Aging and the environment: A research framework

Environmental Health Perspectives

Volumn 113, Issue 9, 2005, Pages 1257-1262

  Geller, Andrew M ^a   Zenick, Harold ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Aging; Environmental health; Exposure; Frailty; Microenvironment; Older adults; Pharmacodynamics; Pharmacokinetics; Polypharmacy

Indexed keywords

ENVIRONMENTAL CHEMICAL; PESTICIDE; XENOBIOTIC AGENT;

AGING; AIR POLLUTION; ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GASTROINTESTINAL DISEASE; HIGH RISK POPULATION; HUMAN; INDOOR AIR POLLUTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARTICULATE MATTER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TOXICOKINETICS; UNITED STATES;

AGED; AGED, 80 AND OVER; AGING; COMMUNICATION; DISEASE SUSCEPTIBILITY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; GOVERNMENT PROGRAMS; HUMANS; PHARMACOKINETICS; RESEARCH; RISK ASSESSMENT; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 25844439617     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.7569     Document Type: Article

References (90)

1. Akman S. 2003. Overview of oxidative stress and cancer. In: Critical Reviews of Oxidative Stress and Aging (Cutler R, Rodriguez H, eds). Hackensack, NJ:World Scientific, 925-954.
2. Baker SR, Rogul M. 1987. Environmental Toxicity and the Aging Process. New York:Alan R. Liss.
3. Bateson TF, Schwartz J. 2004. Who is sensitive to the effects of particulate air pollution on mortality? A case-crossover analysis of effect modifiers. Epidemiology 15:143-149.
4. Birnbaum L. 1991. Pharmacokinetic basis of age-related changes in sensitivity to toxicants. Annu Rev Pharmacol 31:101-128.
5. Borlakoglu J, Haegele K. 1991. Comparative aspects on the bioaccumulation, metabolism, and toxicity with PCBs. Comp Biochem Physiol C100:327-338.
6. Bortz WM II. 2002. A conceptual framework of frailty: a review. J Gerontol 57A:M283-M288.
7. Brooks A, Chadwick C, Gelbard H, Cory-Slechta D, Federoff H. 1999. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823:1-10.
8. Brown J, Zeman K, Bennett W. 2002. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med 166:1240-1247.
9. Buratti F, Volpe M, Meneguz A, Vittozzi L, Testai E. 2003. CYP-specific bioactivation of four organophosphorous pesticides by human liver microsomes. Toxicol Appl Pharmacol 186:143-154.
10. Butler A, Murray M. 1997. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J Pharmacol Exp Ther 280:966-973.
11. Clean Air Act of 1970. 1970. 42 U.S.C. s/s 7401 et. seq. Public law 91-604. http://www.epa.gov/epahome/laws.htm [accessed 18 July 2005].
12. Clewell H, Gentry P, Covington TR, Sarangapani R, Teeguarden JG. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79:381-393.
13. Clewell H, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington R, et al. 2002. Review and evaluation of the potential impact of age-and gender-specific pharmacokinetic differences on tissue dosimtry. Crit Rev Toxicol 32:329-389.
14. Crome P. 2003. What's different about older people? Toxicology 192:49-54.
15. Elias P, Ghadially R. 2002. The aged epidermal permeability barrier: basis for functional abnormalities. Clin Geriatric Med 18:103-120.
16. Food Quality Protection Act of 1996. 1996. Public Law 104-170.
17. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. 2001. Frailty in older adults: evidence for a phenotype. J Gerontol 56A:M146-M156.
18. Frohman L. 1994. A neuroendocrine overview of aging. Neurobiol Aging 15:479-484.
19. Ghadially R, Brown B, Sequeira-Martin S, Feingold K, Elias P. 1995. Aged epidermal permeability barrier: structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Invest 95:2281-2290.
20. Goldman J, Calingasan N, Gibson G. 1994. Aging and the brain. Curr Opin Neurol 7:287-293.
21. Guengerich F, Shimada T. 1991. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
22. Gupta S. 1995. P-glycoprotein expression and regulation. Drugs Aging 7:19-29.
23. Helmuth L. 2003. All in your mind. Science aging knowledge. Environ 8:3-9. Available: http://sagoke.sciencemag.org/cgi/content/full/sageke;2003/8/ns3 [accessed 15 February 2005].
24. Herrlinger C, Klotz U. 2001. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 15:897-918.
25. IPCS. 1993. Environmental Health Criteria 144: Principles for Evaluating Chemical Effects on the Aged Population. Geneva:International Programme on Chemical Safety.
26. Jenkins P, Phillips T, Mulberg E, Hui S. 1992. Activity patterns of Californians: use of and proximity to indoor pollutant sources. Atmosph Environ 26A:2141-2148.
27. Johansson B. 1998. Hypertension. In: The Introduction to the Blood-Brain Barrier: Methodology, Biology, and Pathology (Pardridge W, ed). Cambridge, UK:Cambridge University Press, 427-423.
28. Kim C, Kang T. 1997. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care Med 155:899-905.
29. Kinirons MT, O'Mahoney MS. 2004. Drug metabolism and aging. Br J Clin Pharmacol 57:540-544.
30. Kinney P, Chillrud S, Ramstrom S, Ross J, Spengler J. 2002. Exposures to multiple air toxics in New York City. Environ Health Perspect 110:539-546.
31. Klepeis, NE, Tsang, AM, and Behar, JV. 1996. Analysis of the National Human Activity Pattern Survey (NHAPS) Respondents from a Standpoint of Exposure Assessment. EPA/600/R-96/074. Washington, DC:U.S. Environmental Protection Agency.
32. Kodavanti PRS. 1999. Reactive oxygen species and antioxidant homeostasis in neurotoxicology. In: Neurotoxicology (Tilson HA, Harry G, eds). Target Organ Toxicology Series. Philadelphia:Taylor and Francis, 157-178.
33. Lippman M, Frampton M, Schwartz J, Dockery D, Schlesinger R, Koutradis P, et al. 2003. The U.S. Environmental Protection Agency particulate matter health effects research centers program: a midcourse report of status, progress, and plans. Environ Health Perspect 111:1074-1092.
34. Lu T, Pan Y, Kao S-Y, Li C, Kohane I, Chan J, et al. 2004. Gene regulation and DNA damage in the aging human brain. Nature 429:883-891.
35. Mayersohn M. 1994. Pharmacokinetics in the elderly. Environ Health Perspect 102:119-124.
36. McCord J. 2003. Oxidative stress related disease - overview. In: Critical Reviews of Oxidative Stress and Aging (Cutler R, Rodriguez H, eds). Hackensack, NJ:World Scientific, 883-895.
37. McLean AJ, LeCouteur DG. 2004. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163-184.
38. Michalek H, Fortuna S, Volpe MT, Pintor A. 1990. Age-related differences in the recovery rate of brain cholinesterases, choline acetyltransferase and muscarinic acetylcholine receptor sites after a subacute intoxication of rats with the anticholinesterase agent, isofluorophate. ACTA Neurobiol Exp 50:237-249.
39. Mooradian A. 1997. Central nervous system complications of diabetes milletus - a perspective from the blood-brain barrier. Brain Res Rev 23:210-218.
40. NAS. 2003. Differential Susceptibility of Older Persons to Environmental Hazards. Washington, DC:National Academy of Sciences. Available: http://www.epa.gov/aging/agenda/index.htm [accessed 15 February 2005].
41. National Research Council. 1987. Aging in Today's Environment. Washington, DC:National Academy Press.
42. Naumova E, Egorov A, Morris R, Griffiths J. 2003. The elderly and waterborne Cryptosporidium infection: gastroenteritis hospitalizations before and during the 1993 Milwaukee outbreak. Emerg Infect Dis 9:418-425.
43. O'Mahoney S. 2000. Pharmacokinetics. In: Drugs and the Older Population (Crome P, Ford G, eds). London:Imperial College Press, 58-89
44. Park DC. 2002. The aging mind: an overview. In: Differential Susceptibility of Older Persons to Environmental Hazards. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa.gov/aging/agenda/index.htm [accessed 15 February 2005].
45. Prybys KM, Melville KA, Hanna JR, Gee A, Chyka PA. 2002 Polypharmacy in the elderly: clinical challenges in emergency practice: part I: overview, etiology, and drug interactions. Emerg Med Rep 23(11). Available: http://www.ahcpub.com/ahc_online/emr.html [accessed 5 January 2004].
46. Rea A, Zufall M, Williams R, Sheldon L, Howard-Reed C. 2001. The influence of human activity patterns on personal PM exposure: a comparative analysis of filter-based and continuous particle measurements. J Air Waste Manage Assoc 51:1271-1279.
47. Reaven P. 2003. Roles of oxidative stress and other novel risk factors in cardiovascular disease. In: Critical Reviews of Oxidative Stress and Aging (Cutler R, Rodriguez H, eds). Hackensack, NJ:World Scientific, 896-924.
48. Rehman H, Masson E. 2001. Neuroendocrinology of ageing. Age Ageing 30:279-287.
49. Rodes C, Lawless P, Evans G, Sheldon L, Williams R, Vette A, et al. 2001. The relationships between PM exposures for elderly populations and indoor and outdoor concentrations for three retirement center scenarios. J Expo Anal Environ Epidemiol 11:103-115.
50. Rolan RE. 1994. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 37:125-128.
51. Saarela K, Tirkkonen T, Laine-Ylijoki J, Jurvelin J, Nieuwenhuijsen M, Jantunen M. 2003. Exposure of population and microenvironmental distributions of volatile organic compound concentrations in the EXPOLIS study. Atmosph Environ 37:5563-5575.
52. Safe Drinking Water Act of 1974. 1974. 42 U.S.C. s/s 300f et seq. Public law 93-523. Available: http://www.epa.gov/epahome/laws.htm [accessed 18 July 2005].
53. Sams C, Mason H, Rawbone R. 2000. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol Lett 116:217-221.
54. Schmucker D. 1985. Aging and drug disposition: an update. Pharmacol Rev 37:133-148.
55. Schmucker D. 1998. Aging and the liver: an update. J Gerontol Biolog Sci 53A:B315-B320.
56. Schmucker D. 2001. Liver function and phase I drug metabolism in the elderly. Drugs Aging 18:837-851.
57. Schuurmans H, Steverink N, Lindenberg S, Frieswijk N, Slaets JPJ. 2004. Old or frail: what tells us more? J Gerontol 59A:962-965.
58. Shah G, Mooradian A. 1997. Age-related changes in the blood-brain barrier. Exp Geronotol 32:501-519.
59. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F. 1994. Interindividual variations in human live cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
60. Smith RG, Betancourt L, Sun Y. 2005. Molecular endocrinology and physiology of the aging central nervous system. Endocr Rev 26:203-250.
61. Spencer PS. 1990. Chemical time bombs: environmental causes of neurodegenerative diseases. In: Behavioral Measures of Neurotoxicity (Russell R, Flattau P, Pope A, eds). Washington, DC:National Academy Press, 268-284.
62. Spengler J, Treitman R, Mage D, Soczek M. 1985. Personal exposures to respirable particles and implications for air pollution epidemiology. Environ Sci Technol 19:700-707.
63. Starr J, Wardlaw J, Ferguson K, MacLullich A, Deary I, Marshall I. 2003. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 74:70-76.
64. Thiruchelvam M, McCormack A, Richfield E, Baggs R, Tank A, Di Monte D, et al. 2003. Age-related irreversible progressive nigrastriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18:589-600.
65. Thummel K, Wilkinson G. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
66. U.S. AoA. 2004. A Profile of Older Americans: 2003. Washington, DC:U.S. Administration on Aging. Available: http://www.aoa.gov/prof/Statistics/profile/2003/2003profile.pdf [accessed 16 February 2005].
67. U.S. DoC. 1996. Population Projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. Current Population Reports, P25-1130. Washington, DC:U.S. Department of Commerce. Available: http://www.consus.gov/prod/1/pop/p25-1130/p251130.pdf [accessed 16 February 2005].
68. U.S. EPA. 1997. Exposure Factors Handbook. EPA/600/P-95/002Fa. Washington, DC:U.S. Environmental Protection Agency.
69. U.S. EPA. 1998. A comparison of indoor and outdoor concentrations of hazardous air pollutants. EPA/600/N-98/002. Washington, DC:U.S. Environmental Protection Agency.
70. U.S. EPA. 2000. Strategy for Research on Environmental Risks to Children. EPA/600/R-00/068. Washington, DC:U.S. Environmental Protection Agency, Office of Research and Development.
71. U.S. EPA. 2003a. A national agenda for the environment and the aging: setting priorities for research and education to address environmental hazards the threaten the health of older persons. Fed Reg 68(42):10238-10240.
72. U.S. EPA. 2003b. EPA's Draft Report on the Environment Technical Document. EPA 600-R-03-050. Washington, DC:U.S. Environmental Protection Agency, Office of Research and Development and Office of Environmental Information.
73. U.S. EPA. 2003c. Human Health Research Strategy. EPA/600/R-02/050. Washington, DC:U.S. Environmental Protection Agency, Office of Research and Development.
74. U.S. EPA 2005a. Aging Initiative: Public Listening Sessions. U.S. Environmental Protection Agency. Available: http://www.epa.gov/aging/listening/index.htm [accessed 18 July 2005].
75. U.S. EPA. 2005b. Proceedings of the Aging Americans: Impacts on Ecology and Environmental Quality Workshop. EPA 600/R-05/028. Washington, DC:U.S. Environmental Protection Agency, Office of Research and Development.
76. U.S. Food and Drug Administration. 2002. Preventable Adverse Drug Reactions: A Focus on Drug Interactions. Washington, DC:U.S. Food and Drug Administration. Available: http://www.fda.gov/cder/drug/drugReactions [accessed 15 February 2005].
77. Vestal R. 1989. Aging and determinants of hepatic drug clearance. Hepatology 9:331-334.
78. Vestal R. 1997. Aging and pharmacology. Cancer 80:1302-1310.
79. von Moltke L, Greenblatt D, Harmatz J, Shader R. 1995. Psychotropic drug metabolism in old age: principles and problems of assessment. In: Psychopharmacology: The Fourth Generation of Progress (Bloom F, Kupfer D, eds). New York:Raven Press, 1461-1469.
80. von Moltke L, Greenblatt D, Harmatz J, Shader R. 1995. Psychotropic drug metabolism in old age: principles and problems of assessment. In: Psychopharmacology: The Fourth Generation of Progress (Bloom F, Kupfer D, eds). New York:Raven Press, 1461-1469.
81. Walston J. 2004. Frailty - the search for underlying causes. Sci Aging Knowledge Environ pe4; dot: 10.1126/sageke.2004.4.pe4 [online 28 January 2004]. Available: http://ageke.sciencemag.org/cgi/content/full/2004/4/034 [accessed 18 July 2005].
82. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. 2002. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities. Arch Intern Med 162:2333-2341.
83. Weiss B. 1990. Risk Assessment: the insidious nature of neurotoxicity and the aging brain. Neurotoxicology 11:305-314.
84. Williams R, Creason J, Zweidinger R, Watts R, Sheldon L, Shy C. 2000a. Indoor, outdoor, and personal exposure monitoring of particulate air pollution: the Baltimore Elderly Epidemiology-Exposure Pilot Study. Atmosph Environ 34:4139-4204.
85. Williams R, Suggs J, Creason J, Rodes C, Lawless P, Kwok R, et al. 2000b. The 1998 Baltimore Particulate Matter Epidemiology-Exposure Study. Part 2: Personal exposure assessment associated with an elderly study population. J Exp Anal Environ Epidemiol 10:533-543.
86. Williams R, Wallace L. 2002. Preliminary Particulate Matter Mass Concentrations Associated with Longitudinal Panel Studies: Assessing Human Exposures of High Risk Subpopulations to Particulate Matter. EPA/600/R-01/086. Washington, DC:U.S. Environmental Protection Agency.
87. Wisniewski H, Lossinsky A. 2002. Microvascular pathology in cerebrovascular ischemia. In: Introduction to the Blood-Brain Barrier: Methodology, Biology, and Pathology (Pardridge W, ed). Cambridge, UK:Cambridge University Press, 409-418.
88. Ye J, Garg A, Calhoun C, Feingold K, Elias P, Ghadially R. 2002. Alterations in cytokine regulation in aged epidermis: implications for permeability barrier homeostasis and inflammation. I: IL-1 gene family. Exp Dermatol 11:209-216.
89. Youssef J, Badr M. 1999. Biology of sensescent liver peroxisomes: role in hepatocellular aging and disease. Environ Health Perspect 107:791-797.
90. Zanobetti A, Schwartz J, Gold D. 2000. Are there sensitive subgroups for the effects of airborne particles? Environ Health Perspect 108:841-845.